0.4939

1.46% -0.0073

After Hours: .52 0.0261 +5.28%

Ensysce Biosciences Inc (ENSC)

Overview News Price History Financials Discussions Forecast Stock Split

Ensysce Biosciences Inc stock is traded at $0.4939, with a volume of 551.60K. It is down -1.46% in the last 24 hours and up +19.01% over the past month. Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Previous Close:

$0.5012

Open:

$0.4862

24h Volume:

551.60K

Relative Volume:

0.02

Market Cap:

$9.67M

Revenue:

Net Income/Loss:

$-11.28M

P/E Ratio:

-0.00596

EPS:

-82.86

Net Cash Flow:

$-9.78M

1W Performance:

+14.86%

1M Performance:

+19.01%

6M Performance:

-17.68%

1Y Performance:

-39.32%

1-Day Range:

$0.4804

$0.5256

1-Week Range:

$0.45

$0.5597

52-Week Range:

$0.1412

$2.06

Ensysce Biosciences Inc Stock (ENSC) Company Profile

Name

Ensysce Biosciences Inc

Sector

Healthcare (1180)

Industry

Biotechnology (675)

Phone

(858) 263-4196

Address

7946 IVANHOE AVENUE, LA JOLLA

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

ENSC's Discussions on Twitter

Compare ENSC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ENSC Ensysce Biosciences Inc	0.4939	9.67M	0	-11.28M	-9.78M	-3.01
VRTX Vertex Pharmaceuticals Inc	468.13	120.56B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	750.22	82.44B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	616.55	36.87B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	253.07	32.64B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.39	28.38B	3.30B	-501.07M	1.03B	-2.1146

Ensysce Biosciences Inc Stock (ENSC) Latest News

Nov 28, 2024

Ensysce Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 - Marketscreener.com

Nov 28, 2024

Nov 26, 2024

Ensysce Biosciences Launches Key Trial for Breakthrough Opioid Drug, Backed by $14M NIDA Grant | ENSC Stock News - StockTitan

Nov 26, 2024

Nov 15, 2024

Anson Funds Management LP Acquires New Stake in Ensysce Bioscien - GuruFocus.com

Nov 15, 2024

Ensysce Biosciences Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 15, 2024

Nov 14, 2024

This Is Why Ensysce Biosciences, Inc.'s (NASDAQ:ENSC) CEO Compensation Looks Appropriate - Simply Wall St

Nov 14, 2024

Comparing Ensysce Biosciences (NASDAQ:ENSC) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) - Defense World

Nov 14, 2024

Ensysce Biosciences, Inc. (NASDAQ:ENSC) Short Interest Up 5,514.5% in October - Defense World

Nov 14, 2024

Nov 12, 2024

Ensysce Biosciences Reports Improved Financial Results - TipRanks

Nov 12, 2024

Ensysce Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 12, 2024

Ensysce Biosciences Reports Third Quarter 2024 Financial Results - AccessWire

Nov 12, 2024

Ensysce Biosciences Secures $14M NIH Grant, Swings to Q3 Profit Amid Clinical Progress | ENSC Stock News - StockTitan

Nov 12, 2024

Nov 08, 2024

Ensysce Biosciences granted Nasdaq listing extension By Investing.com - Investing.com Canada

Nov 08, 2024

Nov 07, 2024

Ensysce Biosciences granted Nasdaq listing extension - Investing.com

Nov 07, 2024

Ensysce Biosciences Receives Positive Nasdaq Listing Determination - AccessWire

Nov 07, 2024

Ensysce Biosciences Secures Critical Nasdaq Extension Through 2024 Amid Listing Challenges | ENSC Stock News - StockTitan

Nov 07, 2024

Nov 06, 2024

RA Capital Management, L.P. Acquires New Stake in Ensysce Biosci - GuruFocus.com

Nov 06, 2024

Ensysce Biosciences (NASDAQ:ENSC) Trading Down 9.8% – What’s Next? - Defense World

Nov 06, 2024

Nov 03, 2024

Ensysce Biosciences Presenting at Upcoming Meetings - GuruFocus.com

Nov 03, 2024

Oct 30, 2024

Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket - Benzinga

Oct 30, 2024

Oct 29, 2024

Perceptive Advisors LLC's Strategic Acquisition of Ensysce Biosc - GuruFocus.com

Oct 29, 2024

Oct 24, 2024

3 Penny Stocks to Watch Now, 10/24/24 - TipRanks

Oct 24, 2024

Oct 23, 2024

Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving PremarketStride (NYSE:LRN) - Benzinga

Oct 23, 2024

Oct 22, 2024

Regeneron Pharmaceuticals (REGN) Stock Drops Amid Market Volatility - GuruFocus.com

Oct 22, 2024

Advaxis (ADXS) Sees 112.96% Surge Amid Market Volatility - GuruFocus.com

Oct 22, 2024

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Oct 22, 2024

Oct 18, 2024

Ensysce Biosciences adjusts quorum requirement for stockholder meetings - Investing.com India

Oct 18, 2024

Ensysce Biosciences adjusts quorum requirement for stockholder meetings By Investing.com - Investing.com South Africa

Oct 18, 2024

Oct 16, 2024

When Will Ensysce Biosciences, Inc. (NASDAQ:ENSC) Breakeven? - Simply Wall St

Oct 16, 2024